LIBRA-seq for B Cell Characterization

Antigen-Specific B Cell Characterization

The development of vaccines and therapeutics for infectious diseases, like SARS-CoV-2, relies on characterizing the immune response, in which B cells play a critical role. To accelerate research of COVID-19 and other infectious diseases, we’ve created cutting-edge products for use with innovative new multiomics applications to better understand B cell mediated responses.

What is LIBRA-seq?

Using next-generation sequencing technologies, B cell receptor sequencing is used for immune repertoire analysis; however, this is often limited by the number of antigens that can be screened at once. LIBRA-seq is an emerging multiomics application that breaks these barriers by simultaneously linking antigen specificity with B cell receptor sequencing in single cells. It provides a high-throughput and rapid method to comprehensively understand the B cell response and identify neutralizing antibody populations.

LIBRA-seq utilizes a library of DNA and fluorescently barcoded antigens. Monobiotinylated antigens are used to build antigen multimers with fluorophore- and oligo-conjugated streptavidin. These complexes will specifically bind to B cells that express surface receptors that bind to the antigen. Each antigen is labeled with the same fluorophore so antigen-positive B cells can be fluorescently sorted prior to sequencing. Then, using single-cell droplet encapsulation technology, available through 10x Genomics, single cells are separated and the BCR transcripts, antigen barcodes, and any additional antibody barcodes are indexed. Bioinformatics methods map these sequences to single cells and link BCR sequence to antigen specificity. With the additional use of TotalSeq™-C antibodies, antigen-specific B cells can be further characterized.

Our Solutions for Characterizing the B cell Mediated Response

We provide a ready-to-use system for labeling SARS-CoV-2 antigens with oligonucleotides and fluorophores, removing the need for lengthy workflows associated with synthesizing and conjugating complex molecules to these antigens.

For more information or guidance on how to use these products, contact our technical services team.

Monobiotinylated Recombinant Proteins

The SARS-CoV-2 spike glycoprotein is synthesized as a precursor protein that can be cleaved into an N-terminal S1 subunit and a C-terminal S2 subunit. Binding of the spike protein with host surface proteins initiates membrane fusion and viral entry. Leveraging our recombinant protein expression and modification expertise, we provide high-quality monobiotinylated S protein RBD and S1 subunits.

      Biotinylated Recombinant SARS-CoV-2 S Protein RBD Biotinylated Recombinant SARS-CoV-2 S Protein S1  

TotalSeq™-C Streptavidin Conjugates

Our TotalSeq™ oligonucleotide and fluorophore conjugated streptavidin allows for the multimerization of SARS-CoV-2 antigens, provides a unique antigen barcode, and enables fluorescent-based cell sorting prior to sequencing. Because our TotalSeq™-C products seamlessly integrate with the 10x Genomics Immune Profiling solution for BCR sequencing and RNA characterization, there is no need to validate oligos for overlap with 10x Genomics sequences.

  View all TotalSeq™-C Streptavidin Reagents  

Additional Related Products

TotalSeq™ oligo-conjugated reagents enable protein detection by sequencing and integrate seamlessly into existing single-cell transcriptomics, bulk sequencing, or single-cell genomics workflows.

  Learn more about TotalSeq™ Reagents